Shanghai Kehua Bio-engineering announced that in order to undertake the Shaanxi High-performance Diagnostic Medical Device Innovation Center project, the company's holding subsidiary Xi'an Tianlong Technology Co., Ltd. and its wholly-owned subsidiary Xi'an Huawei Technology Co., Ltd., as well as the company's wholly-owned subsidiary Kehua Bio-engineering Co., Ltd. plan to jointly invest 68 million yuan from their own funds to establish Shaanxi High-performance Diagnostic Technology Co., Ltd. Xi'an Tianlong will contribute 45.56 million yuan in cash, accounting for 67% of the registered capital; Xi'an Kehua will contribute 19.72 million yuan in cash, accounting for 29% of the registered capital; Xi'an Huawei will contribute 2.72 million yuan in cash, accounting for 4% of the registered capital. This investment aims to integrate various advantageous resources, enhance overall competitiveness, align with the company's global strategy, does not constitute a related party transaction, nor a significant asset restructuring. The investment amount is within a controllable range and will not have a significant impact on the company's financial condition and operational results.